Exhibit 99.1




Xtant Medical Announces Third Quarter 2020 Financial Results


BELGRADE, MT, October 29, 2020 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2020.


Third Quarter 2020 Financial Highlights:


  Revenue for the third quarter of 2020 was $14.0 million, up 33% from second quarter 2020 revenue and representing 89% of the $15.7 million revenue for the prior-year period
  Operating expenses in the third quarter of 2020 were $8.5 million, compared to $11.1 million for the prior-year period
  Income from operations was $0.8 million, compared to an operating loss of $0.7 million for the prior-year period
  Net loss incurred in the third quarter of 2020 was $1.4 million, compared to a net loss of $1.9 million for the prior-year period
  Adjusted EBITDA for the third quarter of 2020 was $1.6 million, compared to $0.6 million for the prior-year period


Xtant Medical’s President and CEO, Sean Browne, commented, “We made significant progress in three strategic areas:


  1) The completion of our debt restructuring is a significant event for Xtant since it will dramatically reduce the cost to service our debt and allow us to focus more of our capital and energy on supporting our future growth initiatives.
  2) The realignment of our teams and implementation of new operational procedures to better support our business contributed to our ability to generate operating income during third quarter. I have also challenged our senior management team to continue to look for opportunities to drive even greater efficiencies.
  3) The execution of an agreement with one of the largest group purchasing organizations (GPOs) in the country gives Xtant access to a strategically important new customer base that could contribute to our top line growth.


Our recent initiatives have Xtant well-positioned to focus on growth and market access enabling us to continue delivering on our mission of ‘honoring the gift of donation, so our patients can live as full a life as possible.’”


Third Quarter 2020 Financial Results


Total revenue for the three months ended September 30, 2020 was $14.0 million, representing a decrease of 10.9% compared to $15.7 million in the same quarter of the prior year. This decline in revenue was primarily attributed to the impact of the COVID-19 pandemic and the sudden drop in elective procedures that began in early March; these elective procedures have recovered to some extent as evident by third quarter 2020 revenue representing 89% of third quarter 2019 revenue.


Gross margin for the third quarter of 2020 was 66.0%, compared to 66.2% for the same period in 2019.





Operating expenses for the third quarter of 2020 were $8.5 million, compared to $11.1 million for the third quarter of 2019. The decrease was primarily due to reduced sales commissions, salaries and wages, legal and consulting fees, and executive recruiting fees.


Third quarter 2020 net loss was $1.4 million, or $0.10 per share, compared to third quarter 2019 net loss of $1.9 million, or $0.14 per share.


Adjusted EBITDA for the third quarter of 2020 was $1.6 million compared to $0.6 million for the same period in 2019. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, change in warrant derivative liability, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.


Proposed Rights Offering


Last week, the Company announced details for its proposed rights offering of up to $15 million of common stock. The Company intends to distribute to holders of its common stock as of the November 5, 2020 record date, at no charge, 0.194539 non-transferable subscription rights for each share of common stock held by such holders on such date. Each whole subscription right will entitle the holder to purchase one share of Xtant common stock for $1.07 in cash. In addition, such holders will have an over-subscription privilege, pursuant to which they may purchase additional shares, to the extent not all rights are exercised. The Company expects materials for the rights offering will be mailed on or about November 6, 2020 to holders of its common stock as of the record date, and that the rights offering will close as soon as practicable after the anticipated December 4, 2020 expiration date.


Conference Call


Xtant Medical will host a webcast and conference call to discuss the third quarter 2020 financial results on Thursday, October 29, 2020 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”


About Xtant Medical Holdings, Inc.


Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.


The symbols and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.





Non-GAAP Financial Measures


To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.


Cautionary Statement Regarding Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations that the COVID-19 pandemic will impact revenue for the remainder of 2020 and into 2021 and timing of the proposed rights offering. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing; risks associated with the rights offering; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 5, 2020 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.


Investor Relations Contact


David Carey

Lazar FINN

Ph: 212-867-1762

Email: dcarey@finnpartners.com







(In thousands, except number of shares and par value)



As of

September 30,



As of

December 31,


Current Assets:          
Cash and cash equivalents  $2,741   $5,237 
Trade accounts receivable, net of allowance for credit losses of $746 and doubtful accounts of $500, respectively   7,317    10,124 
Inventories   20,671    16,101 
Prepaid and other current assets   1,656    784 
Total current assets   32,385    32,246 
Property and equipment, net   4,122    4,695 
Right-of -use asset, net   1,799    2,100 
Goodwill   3,205    3,205 
Intangible assets, net   471    515 
Other assets   412    394 
Total Assets  $42,394   $43,155 
Current Liabilities:          
Accounts payable  $2,814   $2,188 
Accrued liabilities   6,043    6,632 
Current portion of lease liability   415    394 
Current portion of financing lease obligations   59    176 
Total current liabilities   9,331    9,390 
Long-term Liabilities:          
Lease liability, less current portion   1,417    1,726 
Long-term debt, plus premium and less issuance costs   79,627    76,244 
Total Liabilities   90,375    87,360 
Stockholders’ Equity (Deficit)          
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $0.000001 par value; 75,000,000 shares authorized; 13,240,831 shares issued and outstanding as of September 30, 2020 and 13,161,762 shares issued and outstanding as of December 31, 2019   -    - 
Additional paid-in capital   181,649    179,061 
Accumulated deficit   (229,630)   (223,266)
Total Stockholders’ Equity (Deficit)   (47,981)   (44,205)
Total Liabilities & Stockholders’ Equity (Deficit)  $42,394   $43,155 







(Unaudited, in thousands, except number of shares and per share amounts)



Three Months Ended

September 30,


Nine Months Ended

September 30,

   2020   2019   2020   2019 
Orthopedic product sales  $13,980   $15,691   $39,207   $47,574 
Other revenue   36    30    115    144 
Total revenue   14,016    15,721    39,322    47,718 
Cost of sales   4,768    5,310    13,913    16,613 
Gross profit   9,248    10,411    25,409    31,105 
Gross profit %   66.0%   66.2%   64.6%   65.2%
Operating expenses                    
General and administrative   3,042    4,228    10,293    12,866 
Sales and marketing   5,270    6,685    15,578    19,499 
Research and development   176    203    529    675 
Total operating expenses   8,488    11,116    26,400    33,040 
Income (Loss) from operations   760    (705)   (991)   (1,935)
Other (expense) income                    
Interest expense   (2,097)   (1,185)   (5,258)   (4,504)
Other (expense) income   -    34    -    (109)
Total Other (Expense)   (2,097)   (1,151)   (5,258)   (4,613)
Net Loss Before Provision for Income Taxes   (1,337)   (1,856)   (6,249)   (6,548)
Provision for income taxes                    
Current and deferred   (23)   (23)   (68)   (68)
Net Loss  $(1,360)  $(1,879)  $(6,317)  $(6,616)
Net loss per share:                    
Basic  $(0.10)  $(0.14)  $(0.48)  $(0.50)
Dilutive  $(0.10)  $(0.14)  $(0.48)  $(0.50)
Shares used in the computation:                    
Basic   13,231,823    13,161,762    13,210,386    13,164,694 
Dilutive   13,231,823    13,161,762    13,210,386    13,164,694 







(Unaudited, in thousands)



Nine Months Ended

September 30,

   2020   2019 
Operating activities:          
Net loss  $(6,317)  $(6,616)
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization   1,658    2,338 
Gain on disposal of fixed assets   (307)   (27)
Non-cash interest   5,245    4,467 
Non-cash rent expense   12    16 
Stock-based compensation   726    256 
Provision for reserve on accounts receivable   296    453 
Provision for excess and obsolete inventory   429    517 
Changes in operating assets and liabilities:          
Accounts receivable   2,463    417 
Inventories   (4,999)   760 
Prepaid and other assets   (890)   240 
Accounts payable   626    (4,216)
Accrued liabilities   (589)   1,053 
Net cash used in operating activities   (1,647)   (342)
Investing activities:          
Purchases of property and equipment   (907)   (403)
Proceeds from sale of fixed assets   173    241 
Net cash used in investing activities   (734)   (162)
Financing activities:          
Payments on financing leases   (115)   (395)
Costs associated with Second Amended and Restated Credit Agreement   -    (149)
Net cash used in financing activities   (115)   (544)
Net change in cash and cash equivalents   (2,496)   (1,048)
Cash and cash equivalents at beginning of period   5,237    6,797 
Cash and cash equivalents at end of period  $2,741   $5,749 





View differences made from one to another to evaluate Xtant Medical Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Xtant Medical Holdings, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account